Aromatic Boron Compounds for Selective Glucose Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current boron-containing compounds face challenges in achieving selectivity towards specific vicinal diols, such as glucose, due to their ability to bind various diols, leading to unpredictable glucose control in diabetes management.
Innovation Solution
Development of novel aromatic boron-containing compounds with specific scaffold geometries and pendant groups that enhance selectivity towards glucose by orienting boron functionalities in three-dimensional space, allowing for controlled binding and release of insulin analogues or conjugates in response to glucose levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If boron-containing compounds are used to bind hydroxyl groups, then binding affinity is improved, but selectivity towards specific vicinal diols deteriorates
Solution Approach 1:
The patent introduces specific pendant groups (carboxylic acid, hydroxyl, amino, or carbonyl) at defined positions on the boron-containing scaffold to create local chemical environments that preferentially interact with glucose hydroxyls. This localized functional group arrangement provides both strong binding affinity and high selectivity for glucose over other diols, resolving the contradiction between general binding strength and specific selectivity.
Solution Approach 2:
The patent employs asymmetric substitution patterns on the boron-containing scaffold, where different pendant groups are positioned at specific locations rather than using symmetric or random arrangements. This asymmetric configuration creates a three-dimensional binding surface that is complementary to the specific geometry of glucose's hydroxyl groups, enabling selective binding while maintaining high affinity.
2Reliability
If binding affinity for diols is increased, then glucose control reliability is improved, but pharmacokinetic control deteriorates
Solution Approach 1:
The patent designs the boron-containing compounds with reversible binding characteristics, allowing the compounds to dynamically associate with and dissociate from glucose and insulin analogues. This dynamic behavior enables the system to respond adaptively to changing glucose levels while maintaining reliable glucose control, as the binding is strong enough to ensure control but reversible enough to allow pharmacokinetic regulation.
Solution Approach 2:
The patent modifies physical and chemical parameters of the boron-containing compounds, such as pKa values, binding constants, and scaffold geometries, to optimize the balance between binding affinity and release characteristics. By tuning these parameters, the compounds achieve reliable glucose control through strong binding while maintaining acceptable pharmacokinetic control for insulin delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate enhanced selectivity and controlled pharmacokinetics of insulin, improving glucose regulation and reducing fluctuations in blood glucose levels.
Implementation Method 1
Boronic acids are generally considered Lewis acids that have a tendency to bind to hydroxyls, because, as Lewis acids, boronic acids can form complexes with Lewis bases such as, for example, hydroxide anions
Implementation Method 2
the boronates can form hydrolysable boronate-ester bonds to the hydroxyl groups of hydroxyl containing molecules
Data Source
AI summary
The present disclosure relates to novel compounds that include one or more aromatic boron-containing groups. The present disclosure further relates to pharmaceutical compositions containing such compounds, and their use in prevention and treatment of disorders, such as hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, metabolic syndrome X, or dyslipidemia, diabetes during pregnancy, pre-diabetes, Alzheimer's disease, MODY 1, MODY 2 or MODY 3 diabetes, mood disorders, and psychiatric disorders.